In a 70‑year‑old man with a prior pulmonary embolism on lifelong apixaban 5 mg twice daily and normal renal function, is it safe to hold apixaban for elective hand surgery, and what are the recommended times to stop it before the procedure and to restart it afterward?

Perioperative Management of Apixaban for Elective Hand Surgery

Direct Answer: Safe to Hold with Specific Timing

For this 70-year-old man with normal renal function on lifelong apixaban 5 mg twice daily for prior pulmonary embolism, it is safe to hold apixaban for elective hand surgery. Stop apixaban 48 hours (2 days) before the procedure and resume 24–48 hours after surgery once adequate hemostasis is confirmed. 1, 2, 3

---

Preoperative Discontinuation Protocol

Standard Timing for Hand Surgery

• Stop apixaban 48 hours before surgery for this patient with normal renal function (creatinine clearance >50 mL/min), as hand surgery is classified as a moderate bleeding risk procedure. 1, 2, 3

• The 48-hour discontinuation period corresponds to approximately 6–7 half-lives of apixaban (half-life 7–8 hours), achieving minimal residual anticoagulant effect at the time of surgery. 3

• Do NOT use bridging anticoagulation with heparin during the 48-hour interruption period—bridging increases major bleeding risk without reducing stroke or systemic embolism in this clinical scenario. 2, 4, 3

Renal Function Considerations

• Calculate creatinine clearance using the Cockcroft-Gault equation (not eGFR) to determine the appropriate hold duration, as this method was used in pivotal trials and FDA labeling. 5, 3

• If this patient has impaired renal function (CrCl 30–50 mL/min), extend the hold period to 72 hours (3 days) to account for reduced drug clearance. 2, 4

• Given his pending CT scan to rule out chronic thromboembolic disease and current shortness of breath, verify renal function before finalizing the discontinuation timeline. 5

---

Postoperative Resumption Strategy

Timing of Restart

• Resume apixaban at least 24 hours after hand surgery once adequate hemostasis is established and there is no active bleeding. 1, 3

• For procedures with higher bleeding risk or if hemostasis is uncertain, consider delaying resumption to 48 hours postoperatively. 4, 3

• The rapid onset of apixaban (peak effect within 3–4 hours) provides prompt anticoagulation upon resumption, eliminating the need for bridging therapy. 2, 3

Dose Considerations

• Restart at the same dose (5 mg twice daily) that the patient was taking preoperatively—do not reduce the dose unless new criteria emerge. 1, 5

• Verify that the patient still meets the appropriate dosing criteria: he should receive 5 mg twice daily unless he meets ≥2 of the following: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. 1, 5

---

Critical Safety Considerations

No Laboratory Monitoring Required

• Do not use INR or aPTT to guide timing—these tests are inconsistent for apixaban and should not be relied upon for surgical clearance. 3, 2

• Standard coagulation tests (INR, aPTT) are not useful for monitoring apixaban effect and provide no actionable information for perioperative management. 4

Thrombotic Risk Assessment

• This patient has a high thrombotic risk due to prior pulmonary embolism requiring lifelong anticoagulation, making the 24–48 hour anticoagulation gap acceptable but necessitating prompt resumption. 2, 3

• The brief interruption period (48 hours preoperatively + 24–48 hours postoperatively) carries minimal thrombotic risk compared with the substantially higher bleeding risk of continuing anticoagulation through surgery. 2

Drug Interaction Screening

• Check for P-glycoprotein and CYP3A4 inhibitors that may prolong apixaban clearance (e.g., ketoconazole, ritonavir, itraconazole)—if present, consider extending the preoperative hold by an additional 24 hours. 4, 1

• Avoid strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) as they markedly reduce apixaban concentrations. 5, 1

---

Common Pitfalls to Avoid

• Do not assume 24 hours is sufficient—hand surgery requires at least 48 hours for patients with normal renal function. 4, 3

• Do not bridge with heparin routinely—this increases bleeding without reducing thrombotic events in most patients undergoing elective procedures. 2, 4, 3

• Do not forget to assess renal function—impaired clearance necessitates longer hold times (72 hours for CrCl 30–50 mL/min). 2, 4

• Do not resume apixaban too early—confirm hemostasis before restarting anticoagulation to avoid surgical site bleeding. 4, 3

• Do not use eGFR for dosing decisions—always calculate CrCl with Cockcroft-Gault, as eGFR can produce significant dosing errors. 5, 3

---

Practical Implementation Algorithm

1. Assess renal function using Cockcroft-Gault equation
2. Screen for drug interactions (P-gp/CYP3A4 inhibitors)
3. Stop apixaban 48 hours before surgery (72 hours if CrCl 30–50 mL/min)
4. Perform hand surgery without bridging anticoagulation
5. Confirm hemostasis postoperatively
6. Resume apixaban 24–48 hours after surgery at the same dose (5 mg twice daily)
7. Monitor for bleeding symptoms clinically (no laboratory tests needed)